Anti-IFNGR1 antibody [EPR24127-89],Abcam,AB280353

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse

Application

ICC/IF, Flow Cyt, IP, WB

Platform ID

BAB910408525

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-IFNGR1 antibody [EPR24127-89]
Cat. No.AB280353
HostRabbit
IsotypeIgG
ReactivityMouse
ApplicationICC/IF, Flow Cyt, IP, WB
ClonalityMonoclonal
Clone NumberEPR24127-89
Concentration0.5235 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (, PubMed : 20926559, PubMed : 27286456). Associates with transmembrane accessory factor IFNGR2 to form a functional receptor (PubMed : 2137461, PubMed : 2530216, PubMed : 2530582, PubMed : 2531896, PubMed : 2532365). Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signaling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to its dimerization, translocation to the nucleus, and stimulation of target gene transcription (PubMed : 19889125). STAT3 can also be activated in a similar manner although activation seems weaker (PubMed : 15284232). IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1 that regulates the JAK-STAT pathway by competing with STAT1 binding to IFNGR1 (PubMed : 15522878). See full target information Ifngr1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.